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Despite development of new antiviral drugs, viral in-
fections are still a major health problem. The most
potent antiviral defensemechanism is the innate pro-
duction of type I interferon (IFN-I), which not only
limits virus replication but also promotes antiviral
T cell immunity through mechanisms, which remain
insufficiently studied. Using the murine lymphocytic
choriomeningitis virus model system, we show here
that IFN-I signaling on T cells prevented their rapid
elimination in vivo. Microarray analyses uncovered
that IFN-I triggered the expression of selected inhib-
itory NK-cell-receptor ligands. Consequently, T cell
immunity of IFN-I receptor (IFNAR)-deficient T cells
could be restored by NK cell depletion or in NK-
cell-deficient hosts (Nfil3–/–). The elimination of
Ifnar1–/– T cells was dependent on NK-cell-mediated
perforin expression. In summary, we identified IFN-I
as a key player regulating the protection of T cells
against regulatory NK cell function.
INTRODUCTION
More than 500 million people worldwide suffer from hepatitis B
virus (HBV) or hepatitis C virus (HCV) infections (Rehermann,
2013; Rehermann and Nascimbeni, 2005). Both virus infections
can lead to chronic disease, resulting in chronic liver inflamma-
tion, tissue damage, end-stage liver failure, and hepatocellular
carcinoma (Rehermann and Nascimbeni, 2005). A critical de-fense mechanism to effectively eradicate viral infections is type
I interferon (IFN-I) production by innate immune cells such as
plasmacytoid dendritic cells (pDCs) (Gilliet et al., 2008). IFN-I
binds to the IFN-I receptor (IFNAR) and not only limits viral
replication (Mu¨ller et al., 1994) but also exhibits regulatory func-
tions during immunity by activating other immune cells (Gonza´-
lez-Navajas et al., 2012; Sadler and Williams, 2008). Earlier
reports indicate that IFN-I exhibits inhibitory effects on T cells
(Petricoin et al., 1997). This can be explained by IFNAR signaling
through the signal transducer and activator of transcription 1
(STAT-1), which blunts T cell effector function, while the
competing STAT4 signaling is essential to promote cytokine
expression of antiviral T cells following IFNAR activation (Nguyen
et al., 2002). Conversely, IFNAR can activate antigen-presenting
cells (APCs), thus promoting T cell activation during viral infec-
tion (Gautier et al., 2005; Santini et al., 2000). Furthermore,
studies using IFNAR-deficient T cells show direct effects of
IFN-I on T cell survival (Aichele et al., 2006; Kolumam et al.,
2005; Le Bon et al., 2006). Consistently, IFN-I is a critical signal
for effector and memory T cell differentiation (Agarwal et al.,
2009; Marshall et al., 2010). However, the underlying mecha-
nisms by which IFN-I affects T cell immunity are not completely
understood.
Natural killer (NK) cells can be activated by IFN-I during viral
infection (Biron et al., 2002) and exhibit cytotoxicity triggered
by the molecule perforin (Ka¨gi et al., 1994). While there is ample
evidence demonstrating that NK cells are important for immunity
against a variety of viral infections, more recent studies indicate
that NK cells can produce immunoregulatory molecules such as
interleukin-10 (IL-10) following activation (Lee et al., 2009; Su
et al., 2001). Consequently, recent reports indicate that NK cells
contribute to antiviral T cell dysfunction during chronic viral
infection (Cook andWhitmire, 2013; Lang et al., 2012; WaggonerImmunity 40, 949–960, June 19, 2014 ª2014 Elsevier Inc. 949
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Figure 1. IFN-I Affects T Cell Immunity
In Vivo
(A) Negatively sorted CFSE labeled CD8+ T cells
from WT and IFNAR1-deficient animals were
stimulated for 24 hr (left panels), 48 hr (middle
panels), and 72 hr (right panels) with anti-CD3
antibody in presence or absence of IFN-4a
(50U/mL, one representative of n = 6 is shown).
(B) CD45.1+ animals were infected with 200 pfu
LCMV WE. 106 negatively sorted CFSE labeled
T cells from P14+ WT and Ifnar1–/– mice were
transferred into infected CD45.1+ mice 2 days
postinfection (p.i.). At day 4 p.i., CFSE expression
on T cells (left panel) and cell number of transferred
cells was analyzed (right panel, error bars show
SEM; n = 3, one of two independent experiments is
shown).
(C and D) Prior to infection, 105 negatively sorted
T cells from P14+ or P14+Ifnar1–/– animals
were transferred into CD45.1+ mice. (C) Gp33-
tetramer+CD8+CD45.2+ T cells were determined in
the blood (left panel) and in spleen tissue (right
panel) 8 days p.i. (percentage of CD8+ cells, error
bars show SEM; n = 5) (D) IFN-g+CD8+CD45.2+
cells were measured after restimulation with the
LCMV epitope gp33 8 days p.i. (percentage of
CD8+ cells, error bars show SEM; n = 5).
(E) We stimulated 2 3 106 negatively sorted CD8+
T cells fromWT and Ifnar1–/–mice in vitro with anti-
CD3 and anti-CD28 antibodies for 72 hr followed
by injection into CD45.1+ animals. Two days
following infection with 200 pfu of LCMV WE,
transferred T cells were measured in spleen tissue
(error bars show SEM; n = 3–4, one of two inde-
pendent experiments is shown).
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NK Cells Kill IFN-I Unresponsive T Cellset al., 2012). These data are accompanied by clinical findings
showing that in cohorts of HCV patients, expression of NK
cell inhibitory receptors correlates with virus control (Khakoo
et al., 2004; Knapp et al., 2010; Paladino et al., 2007). Con-
sistently, NK cell cytotoxicity can be detected in human HCV
patients when compared to healthy controls (Ahlenstiel et al.,
2010). Moreover, after treatment of HCV infected individuals
with IFN-I, NK cell cytotoxicity increases (Edlich et al., 2012).
However, the effectiveness of IFN-I therapy correlates positively
with NK cell cytotoxicity after IFN-I treatment (Edlich et al., 2012).
Furthermore, patients with enhanced NK cell cytotoxicity show
a sustained suppression of HCV during IFN-I treatment (Oliviero
et al., 2013). These data argue against an influence of regulatory
NK cell functions during HCV infection and rather indicate a
beneficial role of NK cells during HCV infection. However, the
role of regulatory factors, which can influence the interaction
between NK cells and T cells, remains still unclear.
Here we show that IFN-I can improve T cell immunity by
protecting antiviral T cells from regulatory NK cell functions.
IFN-I prevented rapid elimination of antiviral T cells during viral
infection in vivo. Microarray analyses uncovered that IFN-I
triggered expression of selective NK cell inhibiting ligands on T
cells. Consequently, NK-cell-deficient animals were able to
mount a functional antiviral T cell response—even in absence
of IFN-I signaling in these T cells. The regulatory effects of
NK cells were dependent on perforin expression in vitro and
in vivo.950 Immunity 40, 949–960, June 19, 2014 ª2014 Elsevier Inc.RESULTS
IFN-I Deficiency Results in Elimination of Proliferating T
Cells In Vivo
IFN-I is a critical factor that triggers T cell immunity in vivo
(Aichele et al., 2006; Kolumam et al., 2005). However, when
negatively sorted T cells from wild-type (WT) and IFN-I recep-
tor-deficient (Ifnar1–/–) mice (Mu¨ller et al., 1994) were stimulated
with anti-CD3 in presence or absence of IFN-I, no difference was
detected in the proliferation rate of T cells (Figure 1A; see also
Figure S1A available online). When we transferred negatively
sorted CFSE-labeled T cells from a mouse carrying the trans-
genic TCR (P14) recognizing the lymphocytic choriomeningitis
virus (LCMV) peptide gp33 (Pircher et al., 1989) into WT animals
following infection with LCMV, we observed as expected, prolif-
eration of the transferredWT T cells (Figure 1B). In sharp contrast
to WT T cells, IFNAR-deficient virus-specific T cells were rapidly
eliminated after transfer into WT animals followed by infection
with LCMV WE (Figure 1B). Transfer of IFNAR-deficient cells
resulted in the absence of functional antiviral T cells during the
course of infection, whereas WT T cells were readily detectable
in infected animals (Figure 1C). Consequently, restimulation with
the virus-specific epitope gp33 induced cytokine production in
WT T cells, whereas there was almost no IFN-g production
detectable in Ifnar1–/– T cells (Figure 1D). The transferred
T cells were eliminated from their host after activation, but naive
T cells from both WT and IFNAR deficient animals were
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NK Cells Kill IFN-I Unresponsive T Cellsdetectable in naive animals throughout the course of the exper-
iment (Figures S1B and S1C). Furthermore, nonspecific viral
infection such as with the cytolytic vesicular stomatitis virus
did not result in diminished quantity of Ifnar1–/– T cells, when
they were not activated (Figure S1D). In addition, when we trans-
ferred WT and Ifnar1–/– P14 cells expressing the congenical
markers CD45.1 and CD90.1, respectively, we observed similar
numbers in the bloodstream (Figure S1E). Moreover, when we
transferred bone marrow harvested from WT and Ifnar1–/– ani-
mals at a ratio of 1:1 into lethally irradiated mice, we observed
no difference in CD8+ T cell numbers (Figure S1F). Next, we
transferred in vitro proliferated T cells into mice followed by
infection with LCMV. Consistently, we observed removal of
proliferated Ifnar1–/– T cells when compared to WT controls (Fig-
ure 1E). These data indicate that absence of IFN-I signalingmight
protect T cells from negative regulators of T cell immunity in vivo.
IFN-I Triggers Expression of Genes Encoding for Major
Histocompatibility Complex Class I and MHC Ib
Molecules on T Cells
To further investigate the mechanism by which T cells show
sustained effector function through IFN-I signaling, we per-
formed microarray analyses on negatively sorted primary CD8+
T cells. T cells were activated with an anti-CD3 antibody in the
presence or absence of IFN-I (500 U/mL IFN-4a). IFN-I regulated
1162 genes in naive T cells, while 270 genes were differentially
expressed in anti-CD3 stimulated T cells after IFNAR activation
(Figure 2A; Figure S2A; Table S1). As expected, expression of
interferon-stimulated genes (ISGs) was significantly higher after
treatment with IFN-I (p(corr) < 0.05) so that expression changes
in IFN-treated cells were clustered independently of anti-CD3
stimulation (Figure S2B). Further on, differentially expressed
IFN-I responsive genes were globally categorized into functional
GeneOntology (GO) classes. Among others, several IFN-related
GO classes showing significant enrichment of differentially ex-
pressed genes could be identified (Figure 2B). Becuase nomajor
differences were observed during T cell proliferation after IFN-4a
treatment in vitro, we speculated that plasma membrane
proteins might play a critical role during the protection of virus
specific T cells in vivo. Among genes encoding for plasma
membrane proteins, genes encoding for MHC I or MHC Ib
molecules were upregulated following IFN-I treatment (Figures
2C and 2D). Taken together, these data indicate that among
genes regulated by IFN-I, expression of genes encoding for
MHC I and MHC Ib molecules was increased.
NK-Cell-Receptor Ligand Expression Is Triggered by
IFN-I
H2 proteins are part of MHC I and MHC Ib molecules, which
can act as ligands of NK cell inhibitory receptors (Vivier et al.,
2011; Vivier et al., 2008). Expression patterns of samples ob-
tained from IFN-I-treated cells clustered when H2 and other
NK-cell-receptor ligands were analyzed, indicating that IFN-I
might trigger the expression of NK-cell-receptor ligands (Fig-
ure 2D). Validation of the genes encoding for NK-cell-receptor
ligands uncovered that expression of several genes were signif-
icantly elevated in response to IFN-I treatment on T cells (Fig-
ure 3A). Although NKG2D ligands were significantly increased
after CD3 stimulation, their expression was not affected byIFN-I in these experiments (Figures S3A and S3B). We also
tested other NK-cell-receptor ligands, but did not identify sta-
tistically different expression in T cells in this setting, neither
during anti-CD3 stimulation nor during incubation with IFN-4a
(Figures S3C–S3G). Next, we analyzed whether MHC I and
Qa-1b protein expression was affected following IFN-I
treatment. Consistent with our gene-expression analyses, Qa-
1b expression was induced on the cell surface of CD8+
T cells after stimulation with anti-CD3 (Figure 3B). However,
coincubation with IFN-4a led to further increase of Qa-1b
expression in a concentration-dependent manner (Figure 3B).
Moreover, MHC I expression was significantly increased on
WT CD8+ T cells when compared to Ifnar1–/– cells (Figures 3C
and 3D). These data indicate that NK-cell-receptor ligands are
regulated by IFN-I and that absence of IFNAR results in limited
expression of the inhibitory NK-cell-receptor ligands MHC I and
Qa-1b in vitro.
NK Cells Target IFNAR1-Deficient T Cells
Our data indicate that the expression of NK-cell-receptor ligands
are affected by IFN-I. We next hypothesized that regulatory NK
cell functions might target antiviral T cells in the absence of
IFN-I. Moreover, when we transferred in vitro stimulated T cells
from WT and Ifnar1–/– animals into LCMV-infected WT hosts,
we observed that absence of IFNAR1 resulted in decreased
expression of Qa-1b (Figure 4A). Consistently, LCMV-specific
T cells from WT mice expressed Qa-1b on the cell surface
when transferred into infected C57BL/6 mice. In the absence
of IFN-I signaling however, Qa-1b expression was reduced
when compared to WT P14 (Figure 4B; Figure S4A). Similar re-
sults were obtained when MHC I expression was determined
(Figure 4C; Figure S4B). When we transferred T cells into naive
animals, we did not observe any expression differences between
WT and IFNAR1-deficient T cells (Figures 4B and 4C). Intermedi-
ate doses of LCMV infection triggers T cell dysfunction of anti-
viral T cells (Lang et al., 2012). As shown by others and us, NK
cell depletion can rescue T cell function with higher doses of
LCMV (Figure S4C) (Cook and Whitmire, 2013; Lang et al.,
2012; Waggoner et al., 2012). After NK cell depletion, LCMV-
specific T cells showed reduced expression of Qa-1b, suggest-
ing that low Qa-1b correlates with elimination of anti-viral T cells
(Figure S4D). Following their transfer, negatively sorted Ifnar1–/–
P14 were rapidly deleted from infected animals. However, after
depletion of NK cells (Koo and Peppard, 1984), the numbers of
IFNAR1-deficient T cells were increased (Figure 4D). Next we
asked whether NK cell depletion might affect prolonged antiviral
T cell immunity of Ifnar1–/– T cells. After NK cell depletion,
Ifnar1–/– P14+ T cells were detectable in increased numbers
8 days after infection when compared to control animals (Fig-
ure 4E). Furthermore, the T cell response was restored in
Nfil3–/–mice.Nfil3–/–mice lackNK cell function but exhibit normal
NKT cell development when compared to WT controls (Gas-
coyne et al., 2009; Kamizono et al., 2009). Consequently, cyto-
kine production by IFNAR1-deficient T cells was highly
increased when compared to their corresponding controls, in
the absence of NK cells, either eliminated by NK cell depletion
or reduced in number and function in Nfil3–/– animals (Figure 4F).
These data indicate that NK cells target antiviral T cells in
absence of IFN-I signaling. Furthermore, these effects wereImmunity 40, 949–960, June 19, 2014 ª2014 Elsevier Inc. 951
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Figure 2. IFN-I Triggers Expression of Genes Encoding for Major Histocompatibility Complex Class I and MHC Ib Molecules on T Cells
(A–C) We stimulated 106 negatively sorted CD8+ T cells with anti-CD3 antibodies in the presence or absence of IFN-4a (500 U/mL). After 6 hr, total RNA was
extracted from cell suspensions andmicroarray analyses were performed (n = 3). (A) Venn diagram of genes regulated by IFN-4a treatment, CD3 stimulation, and
(legend continued on next page)
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NK Cells Kill IFN-I Unresponsive T Cellsrather dependent on NK cell function, because in animals with
competent NKT cell responses but deficient for NK cells,
Ifnar1–/– T cells were recovered. We wondered whether similar
effects could be observed with CD4+ T cells. Consistent with
the described data, Ifnar1–/–Smarta+ T cells, which express a
TCR specific for the LCMV MHC II epitope gp61 as a transgene
(Oxenius et al., 1998), were eliminated by NK cells following
infection with LCMV (Figures S4E and S4F). Moreover, cytokine
production of IFNAR1-deficient antiviral CD4+ T cells could be
increased in absence of NK cells (Figure S4G).
Next, we wondered whether lack of IFNAR1 phenotypically
affected T cell immunity when compared to WT T cells, and
whether NK cell depletion could completely rescue Ifnar1–/–
T cell immunity. When we monitored transferred WT and
Ifnar1–/– T cells over time, we found that removal of IFNAR1-defi-
cient T cells was mainly dependent on the presence of NK cells
and that Ifnar1–/– T cell immunity was similar to WT T cell immu-
nity in absence of NK cells (Figure 5A). Consistently, NK cell
depletion also improved the cytokine production of IFNAR1-defi-
cient T cells (Figure 5B). IFN-g, tumor necrosis factor alpha
(TNF-a), and interleukin-2 (IL-2) production by Ifnar1–/– T cells
was rescued in absence of NK cells (Figure 5B). In line with
this, lysosomal-associated membrane protein-1 (Lamp-1) stain-
ing, indicating degranulation, of Ifnar–/– T cells was also restored
after NK cell depletion (Figure 5B). However, we still observed
significant differences in cytokine production between WT
T cells and Ifnar1–/– T cells in NK-cell-depleted animals (Fig-
ure 5B). Furthermore, we observed higher expression of PD-1
and lower expression of KLRG1 in Ifnar1–/– T cells when
compared to WT T cells (Figure 5C; Figure S5A). This differential
expression of PD-1 was independent of the presence of NK cells
and could potentially contribute to the deficient T cell immunity in
absence of IFN-I (Barber et al., 2006). The differential expression
of KLRG1 suggests an additional role of IFN-I during antiviral
T cell differentiation (Gru¨ndemann et al., 2010; Kaech and Cui,
2012; Kaech et al., 2003). Expression of other factors involved
in regulating antiviral CD8+ T cell immunity such as IL-7R or
TIM-3 (Jin et al., 2010; Jones et al., 2008; Kaech et al., 2003;
Wherry, 2011) were similar or only slightly different between
Ifnar1–/– andWT T cells, when NK cells were depleted (Figure 5C;
Figure S5A). Consistently, when we determined viral titers in
spleen tissue, we observed higher titers in animals that received
Ifnar1–/– T cells (Figure 5D). However, after NK cell depletion, viral
titers were reduced, indicating that in absence of NK cells,
IFNAR1-deficient T cells were capable of eliminating virus-
infected cells (Figure 5D). At later time points, the virus was
cleared from the animals (Figure S5B). When we measured the
IFN-a concentration, we did not observe any differences shortly
after infection (Figure S5C). At day 4 however, serum IFN-a con-
centration in animals receiving Ifnar1–/– T cells were significantly
higher than in other mice (Figure S5C), and this is likely attribut-
able to the higher viral titers due to dysfunctional T cell immunity
(Figures 5A–5D). To investigate whether these effects affected
the interaction of NK cells with T cells in an IFN-I-dependentCD3 stimulation in combination with IFN-4a treatment. (B) Pie diagram of significan
IFN-I (amount of genes regulated within the cluster regulated is shown). (C) C
membrane proteins, which were significantly regulated by IFN-I treatment (p(corr)
(D) Cluster of gene expression of genes encoding for MHC I and MHC Ib molecumanner, we transferred negatively sorted T cells from WT and
Ifnar1–/– mice into the same hosts. Consistent with our previous
findings, we observed higher expression of PD-1 and lower
expression of KLRG1 in Ifnar1–/– T cells, independent of the pres-
ence of NK cells (Figure S5D). However, when we measured the
number of transferred T cells, we detected higher T cell numbers
of Ifnar1–/– T cells in the absence of NK cells when compared to
animals with NK cells (Figure S5E). Furthermore, in line with the
differential PD-1 and KLRG1 expression, we detected a sig-
nificant difference between WT and Ifnar1–/– T cells even in
absence of NK cells (Figure S5E). However, NK cells seemed
to be a critical regulator of T cell immunity in the absence of
IFN-I receptor signaling. Notably, NK cells can also affect T cell
immunity by regulating antigen-presenting cells (Andrews
et al., 2010). In our setting, however, selective increase in
Ifnar1–/– T cells rather points to a direct interaction between
IFNAR1-deficient T cells and NK cells. To further evaluate
whether the observed effects could have been cofounded by
other factors, we used Ifnar1loxp/loxp 3 Cd4-cre+ animals (Kam-
phuis et al., 2006). Similarly, T cell immunity was impaired in
animals, which lack IFNAR1 signaling in T cells (Figure 5E). How-
ever, in the absence of NK cells, antiviral T cells could be recov-
ered in Ifnar1loxp/loxp 3 Cd4-cre+ animals (Figure 5E). Taken
together, these data indicate that NK cells are critical regulators
of T cells deficient in IFN-I signaling in vivo.
NK Cells Target Ifnar1–/– T Cells through Perforin-
Mediated Cytotoxicity
To evaluate whether NK cells target T cells directly, we coin-
cubated sorted WT and Ifnar1–/– T cells from infected animals
with cultured NK cells. NK cells selectively eliminated Ifnar1–/–
T cells while WT T cells were protected from NK-cell-mediated
killing (Figure 6A). Furthermore, NK cells selectively induced
apoptosis in T cells deficient for IFNAR1 when compared to
WT T cells (Figure 6A). During LCMV infection, IFN-I can activate
NK cell cytotoxicity, which is mediated by perforin (Ka¨gi et al.,
1994).While perforin expression of CD8+ T cells is critical to elim-
inate LCMV from the organism, NK-cell-mediated cytotoxicity
does not influence early virus distribution or elimination during
LCMV infection (Lang et al., 2012). To investigate whether per-
forin expression by NK cells affected Ifnar1–/– T cells, we coincu-
bated WT and Ifnar1–/– T cells with perforin-deficient NK cells.
Cell number and cell viability of WT T cells was similar when
the cells were incubated with WT NK cells or perforin-deficient
NK cells. However, Ifnar1–/– T cell numbers and cell viability
were significantly reduced when incubated with WT NK cells in
contrast to perforin-deficient NK cells (Figure 6A), indicating
that the interaction between NK cells and T cells was dependent
on perforin expression in vitro. Next, we performed experiments
with RMA-s and RMA cell lines, which exhibit differential MHC I
expression (Figure S6A). As expected, RMA-s cells, which have
lower MHC I expression, were highly susceptible toward NK-
cell-mediated killing (Figure S6B). Furthermore, the killing of
RMA-s cells was dependent on perforin expression (Figure S6B).tly enriched gene ontology clusters (p < 0.1) after treatment of CD8+ T cells with
hange of gene expression (IFN-4a against PBS) of loci encoding for plasma
< 0.05).
les and encoding for proteins involved in NK cell regulation are shown.
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Figure 4. NK Cells Target Antiviral T Cells in
the Absence of IFNAR Signaling
(A) Negatively sorted CFSE labeled CD8+ T cells
from WT and IFNAR1-deficient animals were
stimulated for 72 hr with anti-CD3 and anti-CD28
antibodies followed by transfer of 23 106 cells into
CD45.1+ animals. At 2 days p.i. with 200 pfu LCMV
WE, Qa-1b expression on transferred T cells was
measured in spleen tissue (error bars show SEM;
n = 3–4).
(B and C) We transferred 106 negatively sorted
CD8+ T cells from P14+ WT and Ifnar1–/– animals
into CD45.1+ hosts followed by no infection or
infection with 23 106 pfu of LCMV WE. (B) Qa-1b,
(C) MHC I (left panel), and H2-Db (right panel)
expression was determined on transferred T cells
20 hr p.i. (error bars show SEM; n = 4, one of two
independent experiments is shown).
(D) Negatively sorted CFSE labeled T cells from
Thy1.1+P14+Ifnar1–/– were transferred into NK cell
depleted and control animals 2 days p.i. with 200
pfu LCMV WE. At 4 days p.i., cell number was
determined (error bars show SEM; n = 4, one of
two independent experiments is shown).
(E and F) We transferred 105 negatively sorted
T cells from Thy1.1+P14+Ifnar1–/– were transferred
into Nfil3–/–, Nfil3+/, and NK-cell-depleted and
control animals prior to infection with 200 pfu of
LCMV WE. (E) Gp33-tetramer+Thy1.1+ T cells are
shown 8 days p.i. (error bars show SEM; n = 5–7).
(F) IFN-g production of Thy1.1+ T cells is shown
8 days p.i. (error bars show SEM; n = 5–7).
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T cells into LCMV infected hosts, we observed their rapid
removal, whereas WT T cells persisted in the infected hosts (Fig-
ure S6C). This rapid depletion was also dependent on NK cells,
since B2m–/– T cells were not eliminated in the absence of NK
cells (Figure S6C).
To evaluate whether NK cells target IFNAR1-deficient T cells
via perforin in vivo, we transferred WT and Ifnar1–/– P14+ cells
into WT and Prf1–/– animals and infected them with LCMV. All
these groups exhibited IFN-I production shortly after infection
(Figure S6D). Consistent with the in vitro data, perforin deficiency
restored the presence of Ifnar1–/– T cells (Figure 6B). Further-
more, IFNAR1 deficient T cells were able to produce cytokinesFigure 3. IFN-I Regulates the Expression of NK-Cell-Receptor Ligands
(A)We stimulated 106 negatively sortedCD8+ T cells with anti-CD3 antibodies in the presence or absence of IFN
from cell suspensions and H2-T24, H2-T23, H2-M3, Clec2d, and Itagv (from left to right) expression was ana
(B–D) Negatively sorted T cells were treated with anti-CD3 antibodies in absence or presence of IFN-4a. (B)
after 20 hr in absence or presence of different indicated IFN-4a concentrations (error bars showSEM; n = 6). (C
after 20 hr of IFN-4a treatment (500 U/mL) (error bars show SEM; n = 4). (D) H2-Db expression was determin
(500 U/mL) (error bars show SEM; n = 4, one of two independent experiments is shown). *p < 0.05, **p < 0.0
Immunity 40, 949–9after restimulation with virus-specific
peptides (Figure 6C), indicating that the
T cells were functional. LCMV cannot be
eliminated in the absence of perforin
(Ka¨gi et al., 1994). However, after transfer
of Ifnar1–/– T cells, only low or no virus ti-
ters were detected in the spleen and othertissues (Figure S6E; data not shown), which indicates that
Ifnar1–/– T cells were capable of eliminating virus-infected cells.
Consistent with the previous data, perforin deficiency did not
affect the increased expression of PD-1 and the lower expres-
sion of KLRG1 on Ifnar1–/– T cells (Figure 6D; Figure S6F), likely
resulting in still significant differences between WT and Ifnar1–/–
T cell immunity in absence of NK cells (Figures 6B and 6C).
Next, we depleted NK cells in one group to assess whether NK
cells might have additional effects on the IFNAR1-deficient virus-
specific T cells. Ifnar1–/– P14+ T cell immunity was restored in
Prf1–/– animals to the same extent as in NK-cell-depleted mice
(Figure 6E). Moreover, there was no further restoration in Ifnar1–/–
P14+ T cell immunity in Prf1–/– mice after NK cell depletion,-4a (500U/mL). After 6 hr, total RNAwas extracted
lyzed by RT-PCR (error bars show SEM; n = 4–6).
Qa-1b expression was determined on CD8+ T cells
) MHC I expression was determined onCD8+ T cells
ed on CD8+ T cells after 20 hr exposure to IFN-4a
1, ***p < 0.001 between the indicated groups.
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Figure 5. NK Cells Regulate Ifnar1–/– T Cell
Number and Function
(A–D) We transferred 105 negatively sorted T cells
from P14+ and P14+ Ifnar1–/–into NK-cell-depleted
and control animals prior to infection with 200 pfu
of LCMV WE. (A) Transferred Gp33-tetramer+
T cells were measured at day 2, 4, and 8 p.i. in
spleen tissue (error bars show SEM; n = 5–8, ***p <
0.001 between P14+Ifnar1–/– transferred control
and NK-cell-depleted animals, ###p < 0.001
between control animals transferred with P14+
Ifnar1–/– and P14+ cells). (B) IFN-g, TNF-a, IL-2, and
Lamp-1-positive transferred cells are shown at day
2, 4, and 8 p.i. (error bars show SEM; n = 4–6,*p <
0.05, **p < 0.01, ***p < 0.001 between P14+Ifnar1–/–
transferred controls and NK-cell-depleted animals,
### p < 0.001 between control animals transferred
with P14+Ifnar1–/– and P14+WT cells, + indicates
p < 0.05 between anti-NK1.1 P14+ and anti-NK1.1
Ifnar1–/–P14+). (C) Surface molecules were moni-
tored on transferred cells on day 4 and 8 p.i. (n =
4–6, one representative is shown). (D) Virus titers of
spleen tissue 4 days p.i. are shown (error bars
show SEM; n = 7).
(E) Ifnar1loxp/loxp 3 CD4-Cre+ and CD4-Cre+
animals with and without NK cell depletion were
infected with 200 pfu of LCMV WE followed by
analyses of gp33-tetramer+CD8+ T cells in spleen
tissue (error bars show SEM; n = 3–5). *p < 0.05,
**p < 0.01, and ***p < 0.001, n.s. indicates not
significant.
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NK Cells Kill IFN-I Unresponsive T Cellsindicating that NK cells target IFNAR1-deficient T cells through
perforin (Figures 6E and 6F). In conclusion, these data indicate
that NK cells target Ifnar1–/– T cells directly and via perforin
expression in vitro and in vivo.
DISCUSSION
In this studywe analyzed the effects of IFN-I on antiviral T cells. In
our in vivo setting, IFNARsignaling protected antiviral T cells from
NK-cell-mediated elimination. Considering these data, we identi-
fied NK cell-receptor ligands on T cells to be regulated by IFN-I
in vitro and in vivo. NK cell deficiency increased Ifnar1–/– P14+
T cell function after viral infection. These effects were triggered
by NK-cell-mediated cytotoxicity because IFN-I signaling-defi-
cient antiviral T cells were functional in perforin-deficient mice.
NK cells might target virus-specific T cells during chronic viral
infection. Human chronic viral infections such as infections with
hepatitis B or hepatitis C virus lead to enhanced cytotoxicity of
NK cells (Ahlenstiel et al., 2010; Oliviero et al., 2009; Rehermann,956 Immunity 40, 949–960, June 19, 2014 ª2014 Elsevier Inc.2013). This NK cell activation might be
triggered by IFN-I (Ahlenstiel et al.,
2010), which can be produced by plasma-
cytoid dendritic cells (pDCs) or Kupffer
cells after sensing HCV RNA (Lau et al.,
2013; Takahashi et al., 2010). Also during
LCMV infection in mice, pDCs contribute
to IFN-I production (Lang et al., 2010),
which is a critical component of NK cell
activation and cytotoxicity (Biron et al.,2002). In humans, the expression of inhibitory NK cell receptors
correlates with elimination of HCV and decreased liver cell dam-
age in human cohorts (Khakoo et al., 2004; Knapp et al., 2010;
Paladino et al., 2007). However, recent studies show that
following IFN-I treatment, immediate increase in serum ALT con-
centration correlated with an increase in NK cell cytotoxicity and
virus elimination, suggesting a protective role of NK cells during
viral induced hepatitis (Ahlenstiel et al., 2011). Furthermore, the
reaction of NK cells to interferon treatment can serve as an
indicator of effectiveness in patients suffering from hepatitis C
virus infection (Oliviero et al., 2013) and predictor of treatment
outcome (He et al., 2006; Sarasin-Filipowicz et al., 2008).
Considering the data obtained in the LCMV model system, NK
cell depletion results in enhanced antiviral T cell immunity, which
triggers virus elimination and prevents chronic viral infection in
mice (Cook and Whitmire, 2013; Lang et al., 2012; Waggoner
et al., 2012). Furthermore, NK cell depletion can improve viral
infections also at later time points during chronic infection
(Waggoner et al., 2014). These seemingly contradictory findings
A B
C
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Figure 6. NK Cells Target Ifnar1–/– T Cells
through Perforin-Mediated Cytotoxicity
(A) We cotransferred 2 3 106 negatively sorted
T cells from P14+ and P14+Ifnar1–/– into NK cell
depleted WT animals, followed by administration
of 23 106 pfu of LCMVWE and 5 mg peptide gp33.
P14+ cells were isolated by FACS on day 2 and
coincubated with IL-2-derived NK cells at the
indicated effector target ratios. Following a 6 hr
incubation, T cells numbers (left panel) and
Annexin V– 7AAD– cells (right panel) were
measured (error bars show SEM; n = 3, one of two
independent experiments is shown, ***p < 0.001
between P14+Ifnar1–/– T cells cocultured with WT
and Prf1/ NK cells, #p < 0.05 between P14+
T cells cocultured with WT and Prf1/ NK cells.
(B–D) We transferred 105 negatively sorted T cells
from P14+ and P14+Ifnar1–/–into prf1/ and con-
trol animals prior to infection with 200 pfu of LCMV
WE. (B) Transferred Gp33-tetramer+ T cells were
measured at day 8 p.i. in spleen tissue (error bars
show SEM; n = 4). (C) IFN-g, TNF-a, and IL-2-
positive transferred cells are shown at day 8 p.i.
(error bars show SEM; n = 4). (D) Surface mole-
cules were monitored on transferred cells on day 8
p.i. (n = 4, one representative is shown).
(E and F) We transferred 105 negatively sorted
T cells from Thy1.1+P14+Ifnar1–/–into NK-cell-
depleted control and Prf1–/– animals prior to
infection with 200 pfu of LCMV WE. (E) Gp33-
tetramer+Thy1.1+ T cells are shown at day 8 p.i.
(error bars show SEM; n = 4). (F) IFN-g production
of Thy1.1+ T cells is shown 8 days p.i. (error bars
show SEM; n = 4, one of two independent exper-
iments is shown). *p < 0.05, **p < 0.01 and ***p <
0.001, n.s. indicates not significant.
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positive clinical benefits could be explained by our data, which
suggest that IFN-I might protect T cells from NK cell cytotoxicity
in addition to their potential antiviral effects during HCV infection.
In patients with strong IFN-I effects, not only might the NK cell
cytotoxicity be higher but also might the protection of T cells
against NK-cell-mediated elimination. These data could also
explain the immediate slight increase of ALT activity following
IFN-I treatment in serum of HCV patients, which could be medi-
ated not only by NK cells but also by increased cytotoxic T cell
activity.
NK cell receptors might orchestrate the regulatory effects of
NK cells. NK cell cytotoxicity can be mediated through a variety
of activating and inhibitory receptors. During HCV and HBV
infection, the activating NK cell receptors NKp30, NKp46,
NKG2C, NKG2D, CD122, and the inhibitory receptor NKG2A
are upregulated (Rehermann, 2013). Considering data from
murine infection models, activating NK-cell-receptor ligands
are upregulated on virus-specific T cells such as NKG2D ligands
(Lang et al., 2012; Rabinovich et al., 2003). Furthermore, CD48Immunity 40, 949–9triggers inhibitory signals on virus-spe-
cific T cells, which is sensed by the NK
cell receptor 2B4 (Waggoner et al.,
2010). In our study, we found no signifi-
cant suppression of NKG2D ligands byIFN-I, arguing against a role of NKG2D ligands in our experi-
mental settings (Figures S3A and S3B). However, we identified
that the expression of inhibitory NK-cell-receptor ligands on
T cells are increased after IFN-I treatment. Involvement of
signaling through other receptors, especially activating NK cell
receptors, is likely, as described in more detail in an accompa-
nyingmanuscript by Crouse et al. (2014). Therefore, during a viral
infection, IFN-I not only activates NK cells but also triggers pro-
tection against regulatory NK cell functions on antiviral T cells.
Furthermore, we identified other factors, which are regulated
by IFN-I on antiviral T cells. Ifnar1–/– T cells exhibited an
increased expression of PD-1, a well-known suppressor of
T cell immunity (Barber et al., 2006). Moreover, IFN-I might
phenotypically affect T cell immunity independently of NK cells,
as evident by differential expression of KLRG1 (Kaech and Cui,
2012; Kaech et al., 2003). These and potentially other mecha-
nisms might contribute to the efficiency of antiviral treatment
by IFN-I, and they remain to be further explored. In conclusion,
IFN-I is a critical regulator for antiviral T cell immunity to protect
against regulatory NK cell functions.60, June 19, 2014 ª2014 Elsevier Inc. 957
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Mice, Viruses, Virus Titration, and Cell Depletion
Nfil3–/– and Ifnar1–/– mice were previously described (Kamizono et al., 2009;
Mu¨ller et al., 1994). P14+ and Smarta+micewere previously described (Oxenius
et al., 1998; Pircher et al., 1989).CD45.1+andB2m–/–micewerepurchased from
Jackson Laboratory (Koller et al., 1990). All mice were on a C57BL/6 genetic
background. All miceweremaintained under specific pathogen-free conditions
and experiments have been approved by commission of the Ontario Cancer
Institute Animal Resource Centre following institutional guidelines or under the
authorization of the LANUV in accordance with German laws for animal protec-
tion. NK cells were depleted with i.v. injection of anti-NK1.1 (clone PK136) as
previously described (Koo and Peppard, 1984; Lang et al., 2012). LCMV strain
WE was originally obtained from F. Lehmann-Grube (Heinrich Pette Institute)
and was propagated in L929 cells as described. Virus titers were measured
with a plaque-forming assay as previously described (Lang et al., 2013). Briefly,
organs were harvested into HBSS and homogenized with a Tissue Lyser
(QIAGEN).MC57cellswere added todiluted virus sampleson24well plates. Af-
ter 3 hr, 1%methylcellulose containingmediumwas added. Forty-eight hr later,
plates were fixed (4% formalin), permeabilized (1%Triton XHBSS), and stained
with anti-LCMV-NP (clone: VL-4) antibody, Peroxidase anti-rat secondary anti-
body. Mice were infected i.v. with 200 or 23 106 pfu of LCMVWE as indicated.
We administrated 23 106 pfu of VSV (Indiana strain) i.v. as indicated.
Purification of T Cells
For T cell purification, single cell suspended splenocytes were enriched
following the manufacturer’s instructions with the pan T cell MACS kit and
the CD8 purification kit (Miltenyi). Purified T cells were labeled with CFSE as
previously described (Invitrogen) (Lang et al., 2012). For NK cell in vitro killer
assay, WT and Ifnar1–/– P14+ T cells were sorted with a FACS Aria III (BD) using
congenicmarkers (CD45.1 for WT and CD90.1 for Ifnar1–/–).
Purification and Culture NK Cells
For NK cell purification, single cell suspended splenocytes were enriched
following the manufacturer’s instructions with the DX5 NK MACS kit (Miltenyi).
For NK culture, sorted NK cells were stimulated with 1,000 U/ml IL-2 (Miltenyi)
for 4 days.
Flow Cytometry Analysis
Flow cytometry was performed as previously described (Lang et al., 2013). For
intracellular cytokine, stain-single suspended splenocytes were incubated with
the LCMV specific peptides gp33. After 1 hr Brefeldin A (eBiosciences) was
added, followed by additional 5 hr incubation at 37C. For Lamp-1 staining,
anti-CD107a antibody (eBiosciences) was added for the 5 hr incubation and
measured after additional staining with anti-CD8 (eBioscience) antibody. For
cytokine production, cells were fixed with 2% formalin after surface stain with
anti-CD8 (eBiosciences), permeabilized with 0.1% Saponin, and stained with
anti-IFN-g, anti-TNF-a, andanti-IL-2 (eBiosciences) for 30minat4C.LCMVspe-
cific T cells andNKG2D ligandstainingswere performedaspreviously described
(Lang et al., 2013; Lang et al., 2012). Cells were incubated with gp33-tetramer or
NKG2D tetramer for 15 min at 37C followed by surface molecule stainings for
30 min at 4C (with anti-CD8, anti-PD-1, anti-KLRG1, anti-CD127, anti-TIM-3,
anti-CD44, anti-CD69, anti-CD45.1, anti-CD45.2, anti-CD90.1, eBioscience).
RT-PCR Analyses
RNA purification and RT-PCR analyses were performed as previously
described according to manufacturer’s instructions (QIAGEN) (Lang et al.,
2013). Gene expression of H2-T24, H2-T23, Clec2d, Itagv, Itgb3, B2m,
Cd48, Cdh1, Pvr, Ulbp1, and Gapdh was performed with kits from Applied
Biosystems. For analysis, the expression of all target genes was normalized
to Gapdh expression (DCt). Gene-expression values were then calculated
based on the DDCt method, with the mean naive MEFs as a control to which
all other samples were compared. Relative quantities (RQ) were determined
with the equation: RQ = 2^-DDCt.
Microarray Analyses
RNA preparations were checked for RNA integrity by Agilent 2100
Bioanalyzer quality control. All samples in this study showed high quality958 Immunity 40, 949–960, June 19, 2014 ª2014 Elsevier Inc.RNA Integrity Numbers (RIN; median = 8). RNA was quantified by photo-
metric Nanodrop measurement. Synthesis of cDNA and subsequent biotin
labeling of cRNA was performed according to the manufacturer’s protocol
(WT Plus Kit; Affymetrix). Briefly, 100 ng of total RNA were converted to
cDNA, followed by in vitro transcription and biotin labeling of cDNA. After
fragmentation labeled cDNA was hybridized to Affymetrix Mouse Gene 2.0
ST Gene Expression Microarrays for 16 hr at 45C, stained by strepatavi-
din/phycoerythrin conjugate and scanned as described in the manufacturer’s
protocol.
Data analyses on Affymetrix CEL files were conducted with GeneSpring GX
software (Vers. 12.5; Agilent Technologies). Probes within each probeset were
summarized by GeneSprings’ ExonRMA16 algorithm after quantile normali-
zation of probe-level signal intensities across all samples to reduce interarray
variability (Bolstad et al., 2003). Input data preprocessing was concluded by
baseline transformation to the median of all samples.
After grouping of samples (three biological replicates each) according
to their respective experimental condition, a given probeset had to be
expressed above background (i.e., fluorescence signal of a that probeset
was detected within the 20th and 100th percentiles of the raw signal distribu-
tion of a given array) in all three replicates in at least one of two, or both con-
ditions to be further analyzed in pairwise comparisons. Differential gene
expression was statistically determined by Welch’s unpaired t test. Resulting
p values were corrected for multiple testing (Benjamini-Hochberg FDR). The
significance threshold was set to p(corr) = 0.05. Hierarchical cluster analysis
was performed with Euclidian similarity measures and Ward’s linkage.
GeneOntology (GO) analyses were done with the DAVID Functional Annota-
tion Tool (http://david.abcc.ncifcrf.gov) (Huang et al., 2009a, 2009b) testing
for enrichment of differentially expressed transcripts in distinct functional
GO categories. Significant GO term enrichment was determined at an
EASE score of p < 0.1.
Statistical Analysis
Data except microarray, which is described above, are expressed as mean ±
SEM. Statistical significance between two groupswas analyzedwith Student’s
t test. For experiments involving analysis of multiple time points, two-way
ANOVA with an additional Bonferroni posttest was used. Mantel-Cox test
was used for analysis of survival curves. p values < 0.05 were considered as
statistically significant.
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